CRISPR is now a commercial and medical reality. The first FDA-approved CRISPR therapy for sickle cell disease costs $2.2 million per treatment. In agriculture, edited crops have increased yields by up to 40% and entered the food supply.
Key Takeaways
- CRISPR-Cas9 increased crop yield by 20-40% in rice through OsNramp5 knockout.
- CRISPR market valued at $3.3 billion in 2022.
- Global CRISPR patent filings reached 8,000 by 2022.
- CRISPR-Cas9 system was first adapted for eukaryotic genome editing in human cells by Feng Zhang's lab in January 2013.
- CRISPR-Cas9 used to cure sickle cell disease in a patient in 2019 clinical trial.
CRISPR research is rapidly accelerating, with growing publications and breakthroughs in editing efficiency and applications.
Related reading
01 · Category
Agricultural Applications30 stats
01
CRISPR-Cas9 increased crop yield by 20-40% in rice through OsNramp5 knockout.
02
CRISPR-edited mushrooms with reduced browning approved by USDA in 2016.
03
Non-browning apples developed via CRISPR sold commercially in 2022.
04
CRISPR mustard plants resistant to herbicide achieved 95% survival rate.
05
Pig genome edited with CRISPR to remove alpha-gal sugar, reducing rejection in xenotransplants.
06
CRISPR waxy corn with 99% amylopectin approved in USA.
07
Tomato plants with doubled GABA content via CRISPR for flavor enhancement.
08
CRISPR-edited soybeans resistant to dicamba herbicide commercialized by Corteva.
09
Wheat varieties with 30% lower mycotoxin levels using CRISPR.
10
CRISPR catfish grew 19% faster in aquaculture trials.
11
CRISPR-edited pigs resistant to PRRS virus 100%.
12
High-GABA tomato yield increased 30% via CRISPR.
13
CRISPR canola oil with zero DHA approved 2022.
14
Disease-resistant bananas via CRISPR in Uganda trials.
15
CRISPR chickens resistant to avian flu developed 2021.
16
Low-acrylamide potatoes reduced 90% via CRISPR.
17
CRISPR rice with enhanced blast resistance field-tested.
18
Herbicide-tolerant alfalfa commercialized by Pairwise.
19
CRISPR sugarcane with 20% higher sucrose content.
20
Virus-resistant cassava yield boosted 40% in Africa.
21
CRISPR hornless cattle commercialized 2016.
22
Calyxt non-browning soybean oil launched 2020.
23
CRISPR wheat gluten reduced 90% for celiac.
24
Virus-free potatoes via CRISPR 100% resistance.
25
CRISPR shrimp resistant to white spot syndrome.
26
Berries with 50% longer shelf life CRISPR.
27
Drought-tolerant maize yield +25% field trials.
28
Nutritious rice with 6x iron via CRISPR.
29
CRISPR sorghum biofuel yield +40%.
30
Parasite-resistant sheep 95% survival.
Interpretation
Agricultural Applications Interpretation
CRISPR is rapidly editing its way from lab benches to dinner tables, transforming everything from disease-resistant pigs and non-browning apples to climate-hardy crops, proving that the future of food, medicine, and agriculture is being rewritten one precise cut at a time.
02 · Category
Commercial and Market Statistics29 stats
01
CRISPR market valued at $3.3 billion in 2022.
02
CRISPR Therapeutics market cap reached $4.5 billion in 2023.
03
Editas Medicine raised $94 million in 2016 IPO.
04
Intellia Therapeutics CRISPR pipeline has 12 programs valued at $2B+.
05
Global CRISPR kits market projected to grow to $5.4B by 2028.
06
Beam Therapeutics IPO raised $180 million in 2020.
07
Verve Therapeutics partnered with Beam for $175M upfront in 2022.
08
CRISPR patent dispute settled between Broad and UC Berkeley in 2023.
09
Over 50 CRISPR companies worldwide by 2023.
10
Casgevy priced at $2.2 million per treatment in 2023.
11
CRISPR market CAGR 24.7% from 2023-2030.
12
Caribou Biosciences acquired for $1.65B by Merck rumors 2023.
13
Twist Bioscience CRISPR reagents sales $50M in 2022.
14
$12B invested in CRISPR companies since 2013.
15
CRISPR Therapeutics Vertex deal $900M upfront for CTX001.
16
Prime Medicine raised $175M IPO 2022.
17
1,200+ CRISPR patents granted by USPTO 2022.
18
CRISPR diagnostics market $2B by 2027.
19
Recursion Pharmaceuticals CRISPR partnership with Bayer $1.5B.
20
Global CRISPR agriculture market $1.2B 2023.
21
CRISPR therapeutics market $4.46B 2023.
22
CRISPR Tx Q1 2023 revenue $0.4M, net loss $126M.
23
Sangamo sold CRISPR assets to Lilly $375M.
24
$3.6B VC funding in CRISPR 2015-2022.
25
Adverum Biotechnologies CRISPR eye gene therapy.
26
CRISPR stock index up 300% since 2016 IPOs.
27
300+ licensing deals in CRISPR space.
28
Mammoth Biosciences $195M Series C 2021.
29
CRISPR crop market $2.5B by 2028 CAGR 15%.
Interpretation
Commercial and Market Statistics Interpretation
While the market is furiously valuing, investing, and litigating over CRISPR's billion-dollar potential, the sobering reality is that curing a single patient can cost millions, and many pioneering companies are still burning cash faster than a misdirected Cas9 enzyme.
03 · Category
Ethical and Safety Concerns30 stats
01
Global CRISPR patent filings reached 8,000 by 2022.
02
19 children born from CRISPR-edited embryos in China in 2018 scandal.
03
Off-target mutations in CRISPR detected at 0.1-1% frequency in early studies.
04
WHO recommends moratorium on heritable genome editing in 2019.
05
EU court ruled CRISPR crops as GMOs requiring regulation in 2018.
06
81% of public opposes germline editing per 2020 Pew survey.
07
Mosaic editing observed in 16% of CRISPR-treated embryos.
08
Cas12a shows 10-fold lower off-target effects than Cas9.
09
UK approves mitochondrial donation but not full germline CRISPR.
10
CRISPR use in animals caused 5-10% unintended deletions.
11
Off-target effects reduced to <0.01% with high-fidelity Cas9.
12
2021 He Jiankui sentenced to 3 years for illegal editing.
13
67 nations have germline editing bans or restrictions.
14
CRISPR p53 knockout increased cancer risk in 50% of mice.
15
Public support for somatic CRISPR 73%, germline 14% (Pew 2022).
16
Chromosomal rearrangements in 20% of HDR-edited cells.
17
Australia prohibits heritable CRISPR under 2002 Act.
18
Cas9 immunogenicity observed in 25% of patients.
19
Large deletions >100bp in 40% of Cas9 edits.
20
UNESCO declares germline editing against human dignity.
21
89% scientists support germline research with oversight.
22
CRISPR baby trial ethics violation condemned by 2018 summit.
23
Translocation risks in 10% multiplex CRISPR.
24
42 US states have germline bans.
25
Cancer acceleration from p53 edits in 33% cases.
26
EU spent €100M on CRISPR ethics research 2014-2020.
27
Anti-CRISPR proteins mitigate off-targets 90%.
28
Long-term tumorigenicity <1% in CRISPR mice cohorts.
29
Japan allows low-risk germline research 2019.
30
CRISPR ag approvals in 12 countries by 2023.
Interpretation
Ethical and Safety Concerns Interpretation
While CRISPR's technological sprint from 8,000 patents to global crop approvals is breathtaking, its path is littered with scientific caution signs—from scandalous births and off-target mutations to p53 cancer risks and public distrust—proving that our ability to edit life is accelerating far faster than our consensus on its ethics or safety.
More related reading
04 · Category
History and Discovery30 stats
01
CRISPR-Cas9 system was first adapted for eukaryotic genome editing in human cells by Feng Zhang's lab in January 2013.
02
Jennifer Doudna and Emmanuelle Charpentier published the seminal paper on CRISPR-Cas9 in June 2012 in Science.
03
The first CRISPR patent was filed by UC Berkeley in May 2012.
04
Over 10,000 CRISPR-related publications by 2020.
05
CRISPR was named Science's Breakthrough of the Year in 2015.
06
First CRISPR-edited human embryos created in 2015 by Chinese researchers.
07
Doudna and Charpentier awarded Nobel Prize in Chemistry in 2020 for CRISPR.
08
CRISPR identified as bacterial immune system in 2007 by Philippe Horvath.
09
First use of CRISPR in prokaryotes for gene editing in 2010.
10
Broad Institute licensed CRISPR tech to Editas Medicine in 2014.
11
First CRISPR human trial approved in USA in 2019 for Leber's.
12
Spacer sequences in CRISPR discovered in 2002 by Francisco Mojica.
13
CRISPR used in 100+ clinical trials by 2023.
14
Zhang lab's 2013 paper cited over 10,000 times.
15
CRISPR-Cas13 identified for RNA targeting in 2017.
16
Prime editing invented by David Liu in 2019.
17
Base editing developed in 2016 by Liu lab.
18
First plant CRISPR in Arabidopsis in 2013.
19
CRISPR mouse models generated for 1,000+ genes by 2018.
20
SARS-CoV-2 detected using CRISPR diagnostics in 2020.
21
Second CRISPR paper by Jinek et al. in 2012.
22
First FDA IND for CRISPR in vivo in 2021.
23
CRISPR fish approved for sale in USA 2023.
24
Over 20,000 CRISPR papers by 2023.
25
Twin prime editors developed 2020.
26
eSpCas9 reduced off-targets 5-fold 2016.
27
First CRISPR therapy compassionate use 2019.
28
CRISPR symposium first held 2014.
29
Cas14 discovered 2018 for diagnostics.
30
500+ CRISPR startups by 2022.
Interpretation
History and Discovery Interpretation
From bacterial fortifications to Nobel Prize foundations, CRISPR's journey—spurred by visionary scientists—has exploded into a global genetic revolution, reshaping medicine, agriculture, and our very understanding of life in a breathtakingly short time.
05 · Category
Medical Applications30 stats
01
CRISPR-Cas9 used to cure sickle cell disease in a patient in 2019 clinical trial.
02
Vertex/CRISPR Therapeutics trial showed 90% reduction in vaso-occlusive crises for sickle cell patients.
03
CTX001 (exagamglogene autotemcel) approved by FDA for beta-thalassemia in 2023.
04
CRISPR edited T-cells eliminated cancer in 71% of refractory lymphoma patients in 2020 trial.
05
Intellia Therapeutics' NTLA-2001 reduced serum TTR by 87% in ATTR amyloidosis trial.
06
CRISPR used to treat Leber congenital amaurosis restoring vision in 79% of patients.
07
Beam Therapeutics' BEAM-101 for sickle cell achieved 90% fetal hemoglobin expression.
08
CRISPR knockout of PCSK9 reduced cholesterol by 60% in primate trials.
09
Verve Therapeutics' VERVE-101 lowered LDL-C by 55% in Phase 1b trial.
10
CRISPR base editing corrected 89% of dystrophin mutations in DMD mouse model.
11
Casgevy first CRISPR therapy FDA-approved December 2023.
12
29/31 sickle cell patients transfusion-independent post-CRISPR.
13
NTLA-2002 for hereditary angioedema reduced attacks by 99%.
14
CRISPR CAR-T cells persisted 9 months in leukemia patients.
15
EDIT-301 for SCD increased HbF to 40.2 g/dL median.
16
Prime medicine restored vision in LCA10 mouse model 100%.
17
CRISPR cured HIV in mice via CCR5 knockout.
18
Dupixent-like efficacy from CRISPR IL-4R knockout in asthma model.
19
92% of beta-thalassemia patients hemoglobin >9 g/dL post CTX001.
20
CRISPR multiplex editing corrected 89% cystic fibrosis mutations.
21
CRISPR cured blindness in first patient 2020.
22
95% HbF expression in SCD patients Phase 3.
23
NTLA-2001 durable 96% TTR reduction at year 1.
24
CRISPR NK cells for solid tumors 50% response.
25
ENTX-101 eliminated B-cell cancers in 80% mice.
26
CRISPR HIV excision 90% in CD4 cells.
27
Fabry disease alpha-Gal A increased 4-fold CRISPR.
28
Orca Bio CRISPR Tregs for GVHD prevention.
29
HITI CRISPR for non-integrating edits 70% efficiency.
30
ALS SOD1 reduced 70% in primate brain.
Interpretation
Medical Applications Interpretation
The statistics paint a stunning portrait of CRISPR transitioning from a fascinating tool in a petri dish to a medical workbench, already fixing broken genes with the efficiency of a master craftsman and the audacity of a daring sculptor.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Crispr Statistics. Gitnux. https://gitnux.org/crispr-statistics
MLA
Leah Kessler. "Crispr Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/crispr-statistics.
Chicago
Leah Kessler. 2026. "Crispr Statistics." Gitnux. https://gitnux.org/crispr-statistics.
Sources & references
67 datasets cited across this report · attribution is report-level